Searchable abstracts of presentations at key conferences in endocrinology

ea0019p10 | Bone | SFEBES2009

Bone mineral density and body composition in adult men and women with CAH hyperplasia: congenital adrenal hyperplasia adult study executive

Han T , Willis D , Wild S , Ross R , Conway G , CAH Adult Study Executive CaHASE

Objectives: To assess bone mineral density (BMD) and body composition in adults with congenital adrenal hyperplasia (CAH).Setting: Endocrine clinics in seventeen centres throughout the UK participating in CaHASE, a Society for Endocrinology project.Study design and subjects: Cross-sectional survey of 203 adults with CAH (65 men, 138 women: median age 33 (range 18–70) years). Hundred and sixty six patients were classified as cl...

ea0029oc9.5 | Endocrine Tumours & Translation | ICEECE2012

Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients

Christ E. , Forrer F. , Wild D. , Clerici T. , Braendle M. , Maecke H. , Ell P. , Caplin M. , Gloor B. , Reubi J.

Background: Although biochemical diagnosis of endogenous hyperinsulinemic hypoglycemia is straightforward, surgical removal of an insulinoma is hampered by difficulties to localize it using conventional radiological procedures (endosonography, MRI, CT-imaging techniques).In vitro data suggest that human insulinoma cells exhibit a high density of GLP-1R. 111In-exendin-4 is a 111In labeled GLP-1R agonist that binds with high affinity to GLP-1R and m...

ea0029p53 | Adrenal cortex | ICEECE2012

Relationship of current glucocorticoid dose with metabolic outcomes in CAH: analysis of the United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE) cohort

Han T. , Stimson R. , Rees A. , Krone N. , Willis D. , Wild S. , Conway G. , Arlt W. , Walker B. , Ross R. , CaHASE X.

We have previously reported the following metabolic abnormalities were common in 203 adult patients with CAH: obesity (41%), hypercholesterolemia (46%), insulin resistance (29%), osteopenia (40%) and osteoporosis (7%) (Arlt et al. JCEM 2010 95 5110–21). The CAH patients were taking different glucocorticoid therapies at various doses (n=196): hydrocortisone (n=25 M, 26 W), prednisolone (n=21M,67W), dexamethasone (n=15M,22W) or comb...